Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Hilton Baltimore Inner Harbor

Apr 05, 2027 8:00 AM - Apr 07, 2027 12:30 PM

401 W Pratt Street, Baltimore, MD 21201, USA

Global Pharmacovigilance and Risk Management Strategies Conference

Early Bird Rate Ends

DAYS

HOURS

MINUTES

SECONDS

Session 4: Clinical Trial Safety Data Evaluation, From Ongoing Monitoring to Risk Characterization

Session Chair(s)

Ranjeeta  Sinvhal, MD

Ranjeeta Sinvhal, MD

Executive Medical Director, Medical Safety, AbbVie, United States

Bethany  Van Veen

Bethany Van Veen

CEO and Founder, Perspective Pharmacovigilance, United States

Clinical trial pharmacovigilance requires a structured and scientifically robust approach to safety monitoring, signal evaluation, and risk characterization throughout drug development. This session will provide practical perspectives on reviewing and interpreting clinical trial safety data across the development lifecycle, from ongoing blinded studies to post-unblinding benefit-risk assessments. Experts from industry and regulatory backgrounds will discuss best practices for aggregate safety review, evaluation of adverse events of special interest (AESIs), integration of laboratory and clinical data, effective data visualization, and approaches to defining adverse drug reactions (ADRs) and risks for Risk Management Plans (RMPs). Through case examples and panel discussion, attendees will gain practical insights into modern approaches for translating clinical trial safety data into meaningful development and regulatory decisions.

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.